Enteric viruses
Líneas de investigación
Content with Investigacion .
Virus entéricos
1. Vigilancia microbiológica y epidemiológica a nivel nacional de las infecciones causadas por enterovirus y parechovirus y de los casos de parálisis flácida aguda en menores de 15 años. Caracterización, asociación clínica y epidemiología molecular.
2. Investigación de los enterovirus y parechovirus que causan infecciones neurológicas y sistémicas severas en población pediátrica. Estudio de los factores virológicos implicados en la patogenicidad.
3. Estudio virológico de muestras ambientales (aguas residuales y tratadas para consumo) de la CAM.
4. Estudio virológico (diagnóstico y caracterización) de las infecciones gastrointestinales causadas por virus (norovirus, rotavirus y otros). Epidemiología molecular y caracterización de brotes.
Investigación y vigilancia de los poliovirus y la poliomielitis
El Laboratorio de Enterovirus (actualmente de Virus Entéricos) del CNM fue designado Laboratorio Nacional de Poliovirus en 1998 y desde entonces es certificado anualmente por la OMS, como parte del Plan Global de Erradicación de la Poliomielitis. Es responsable, junto a 3 laboratorios primarios en 3 CCAA, de la vigilancia de la poliomielitis a nivel nacional, estudiando e investigando (clínica, epidemiológica y virológicamente) todos los casos compatibles, incluidos los de parálisis flácida aguda en menores de 15 años (enfermedad de notificación obligatoria) para descartar la presencia y circulación de poliovirus en España.
Además, desde 1999 (y gracias a un convenio con el CYII) posee toda la infraestructura y metodología necesaria para realizar vigilancia medioambiental en aguas, tanto para medir la calidad de las aguas potables de ETAP, como para monitorizar la excreción de virus por parte de la población con el estudio de la presencia de poliovirus y otros enterovirus en aguas residuales de EDAR. Esto ha permitido que, a partir de marzo de este año, se estén realizando, además, ensayos de presencia de SARS-CoV-2 en las muestras procedentes de diferentes EDAR situadas en la CAM.
Investigación y referencia en infecciones por enterovirus y parechovirus
El Laboratorio también es Laboratorio de Referencia para las infecciones por Enterovirus y Parechovirus realizando: 1) el diagnostico virológico en muestras clínicas; 2) la caracterización de todos los enterovirus y parechovirus detectados (Programa de Vigilancia Microbiológica del CNM); 3) el desarrollo, mantenimiento y transferencia de métodos de diagnóstico y tipado, tanto moleculares como de cultivo viral; y 4) la investigación para profundizar en el conocimiento de aquellos virus implicados en casos de excepcional importancia clínica o epidemiológica. La larga experiencia del grupo en la propagación de cultivos virales de enterovirus y en técnicas celulares y moleculares de caracterización, ha permitido que el CNM posea una amplia colección de cepas, muy valiosa para la investigación de estos virus.
Investigación y referencia en infecciones gastrointestinales causadas por virus
Desde 2016, el laboratorio realiza: 1) el diagnostico virológico de Norovirus, Rotavirus, Adenovirus 40/41, Astrovirus y otros virus productores de gastroenteritis aguda en muestras clínicas; 2) el genotipado de los virus detectados y la caracterización de brotes; 3) el desarrollo y mantenimiento de métodos de diagnóstico y genotipado; y 4) la investigación básica y epidemiológica de aquellos virus de mayor importancia clínica.
Proyectos de investigación
Content with Investigacion .
Proyectos de investigación financiados en los últimos 5 años
- Investigación de las infecciones neurológicas graves en niños causadas por enterovirus emergentes en España: EV-A71 y EV-D68 (PI18CIII/00017). Financiación: ISCIII. 2019-2021. IP: M. Cabrerizo
- Metagenomic sequencing to identify viral etiologies in undiagnosed cases of meningitis and encephalitis (PI20CIII/00005). Financiación: ISCIII. 2021-2023. IP: M.D. Fernández-García
- Investigación en infecciones por enterovirus y parechovirus que causan patologías neurológicas y sistémicas graves en población infantil (PI15CIII/00020). Financiación: ISCIII. 2016-2019. IP: M. Cabrerizo
- Aplicación de la secuenciación masiva para el diagnóstico de infecciones neurológicas de origen vírico no filiadas (PI-0216-2019). Financiación: Junta de Andalucía, Consejería de Salud y Familias. 2019-2021. IP: M.D. Fernández-García (2019)/ Ana Belen Pérez-Jiménez (2020-21)
- Epidemiología y patogenia molecular de los enterovirus y parechovirus asociados a sepsis e infecciones neurológicas en población infantil en España (PI12/00904). Financiación: ISCIII. 2013-2016. IP: M. Cabrerizo
Otros proyectos de investigación relevantes en los que ha colaborado o colabora el grupo
- Dinámica de colonización e infección por E. coli enteroagregativo en poblaciones pediátricas y su asociación con la composición de la microbiota intestinal mediante análisis metagenómico (PI18CIII/00043). Financiación: ISCIII. 2019-2021. IP: S. Sánchez
- Paving the way for implementing a syndromic diagnostic scheme at the CNM for the diagnosis of diarrhoea-causing pathogens in stool samples based on molecular and metagenomics methods (PI19CIII/00029). Financiación: ISCIII. 2020-2022. IP: D. Carmena
- Engineering lactobacilli for intranasal immunization against the emerging enterovirus D68 (EV-D68) infections and prevention of acute flaccid myelitis. Financiación: ESCMID. 2019-2020. IP: M.C. Póvoa-Cabral
- Análisis epidemiológico y virológico de los agentes virales incluidos en la vacuna triple vírica: nuevos retos (PI15CIII/00023). Financiación: ISCIII. 2016-2019. IP: F. de Ory/A. Fernández
- Epidemiología general y molecular de la hepatitis E en España: ¿una zoonosis emergente? (PI080865). Financiación: ISCIII. 2009-2012. IP: M. Fogeda
- Etiología de las meningitis y encefalitis víricas en España (PI07/90154). Financiación: ISCIII. 2008-2010. IP: F. de Ory
- Investigation of the dynamics and geography of the spread of recombinant forms of human enteroviruses (WT081173MA). Financiación: Wellcome Trust. 2007-2010. IP: P. Simmonds.
Convenios
- Servicios para la realización de estudios virológicos previstos en el agua procedentes para Canal de Isabel II-Gestión (MVP-207/18). Financiación: Canal de Isabel II. 2018-2021. IP: M. Cabrerizo
- Análisis virológico en muestras de aguas procedentes del Canal de Isabel II (MVI-1005/99). Financiación: Canal de Isabel II. 2016-2017. IP: M. Cabrerizo
Publicaciones destacadas
Human Immunodeficiency Virus Type 1 Two-Long Terminal Repeat Circles: A Subject for Debate. Olivares I, Pernas M, Casado C, López-Galindez C
Human Immunodeficiency Virus Type 1 Two-Long Terminal Repeat Circles: A Subject for Debate. Olivares I, Pernas M, Casado C, López-Galindez C. AIDS Rev. 2016 Jan-Mar,18(1):23-31. PMID: 26936759
DOIHIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity. Pernas M, Sanchez-Merino V, Casado C, Merino-Mansilla A, Olivares I, Yuste E, Lopez-Galindez C
HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity. Pernas M, Sanchez-Merino V, Casado C, Merino-Mansilla A, Olivares I, Yuste E, Lopez-Galindez C. PLoS One. 2015 Aug 10,10(8): e0134054. doi: 10.1371/journal.pone.0134054. eCollection 2015.
DOIMetabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation FRONTIERS IN IMMUNOLOGY.
3 Ceballos, Francisco C.; Virseda-Berdices, Ana; Resino, Salvador; et al; Jimenez-Sousa, Maria Angeles. (19/19). 2022. Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation FRONTIERS IN IMMUNOLOGY. ISSN 1664-3224.
Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients.
4 Virseda-Berdices, Ana; Rojo, David; Martinez, Isidoro; et al; Jimenez-Sousa, Maria Angeles. (14/14). 2022. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. BIOMEDICINE & PHARMACOTHERAPY. 147:112623. ISSN 1950-6007.
HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients FRONTIERS IN IMMUNOLOGY.
7 Brochado-Kith, Oscar; Martinez, Isidoro; Berenguer, Juan; et al; Jiménez-Sousa, Maria Angeles (‡, AC); Resino, Salvador (‡, AC). (13/13). 2021. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients FRONTIERS IN IMMUNOLOGY. 12:723196. ISSN 1664-3224.
HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization
2. Valle-Millares D; Brochado-Kith O; Gómez-Sanz A; et al;Fernández-Rodríguez A (AC). (17/17). 2021. HCV eradication with DAAs differently affects HIV males and females: a whole miRNA sequencing characterization Biomedicine and Pharmacotherapy. Elsevier.
DOIPlasma miRNA profile at COVID-19 onset predicts severity status and mortality
3. Fernández-Pato A; Virseda-Berdices A; Resino S; et al; Fernández-Rodríguez A (AC). (20/20). 2022. Plasma miRNA profile at COVID-19 onset predicts severity status and mortality Emerging Microbes and Infections. Taylor & Francis Online. ISSN 2222-1751.
DOIDiagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis
4. Sepúlveda-Crespo D; Treviño-Nakoura A; Bellon JM; Jiménez-Sousa MA; Ryan P; Martínez I; Fernández-Rodríguez A (AC); Resino S. (7/8). 2022. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis.Journal of clinical microbiology. pp.e0133122. ISSN 0095-1137.
DOIMetabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation
6. Ceballos FC; Virseda-Berdices A; Resino S; et al; Jiménez-Sousa MÁ (AC). (19/19). 2022. Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation.Frontiers in immunology. 13, pp.925558. WOS (78)
DOINovel genes and sex differences in COVID-19 severity
7. Cruz R; Almeida SD; Heredia ML; et al; Fernández-Rodríguez A; Carracedo Á. (51/168). 2022. Novel genes and sex differences in COVID-19 severity. Human molecular genetics. ISSN 0964-6906.
DOIDifferent HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients
8. Valle-Millares D; Brochado-Kith O; Martín-Carbonero L; et al; Fernández-Rodríguez A (AC). (22/22). 2021. Different HCV exposure drives specific miRNA profile in PBMCs of HIV patients Biomedicines. MDPI. 9-11, pp.1627.
DOIAre Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?
9. Ceballos F; Ryan P; Blancas R; et al; Fernández-Rodríguez A (AC); Jiménez-Sousa MA. (19/20). 2021. Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality? Frontiers in Medicine. Frontiers. 8-718053.
DOITelomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals
12 . Molina-Carrión S; Brochado-Kith, Oscar; González-García J; et al; Angeles Jimenez-Sousa, Maria. (16/16). 2020. Telomere length increase in HIV/HCV-coinfected patients with cirrhosis after HCV eradication with direct acting antivirals. JOURNAL OF CLINICAL MEDICINE. MDPI. ISSN 2077-0383.
DOIMicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection
15. Brochado-Kith, Oscar; Gomez-Sanz, Alicia; Real LM; et al; Fernandez-Rodriguez, Amanda (AC). (16/16). 2019. MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection JOURNAL OF CLINICAL MEDICINE. MDPI. 7. ISSN 2077-0383.
DOIPersistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination
Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination. Rodríguez-Mora S, Pérez-Lamas L, Solera Sainero M, Torres M, Sánchez-Menéndez C, Corona M, Mateos E, Casado-Fernández G, Alcamí J, García-Pérez J, Pérez-Olmeda M, Murciano-Antón A, López-Jiménez J, García-Gutiérrez V, Coiras M (AC). Cancers 2023, 15(8), 2344. doi: 10.3390/cancers15082344. PMID: 37190272.
PUBMED DOISustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to Avoid a Fatal Outcome
Sustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to Avoid a Fatal Outcome. Casado-Fernández G, Corona M, Torres M, Saez AJ, Ramos-Martín F, Manzanares M, Vigón L, Mateos E, Pozo F, Casas I, García-Gutierrez V, Rodríguez-Mora S, Coiras M (AC). Int J Environ Res Public Health. 2023 Jan20;20(3):1947. doi: 10.3390/ijerph20031947. PMID: 36767310.
PUBMED DOIDasatinib: effects on the macrophage phospho proteome with a focus on SAMHD1 and HIV-1 infection
Dasatinib: effects on the macrophage phospho proteome with a focus on SAMHD1 and HIV-1 infection. Williams ESCP, Szaniawski MA, Martins LJ, Innis EA, Alcamí J, Hanley TM, Spivak AM, Coiras M, Planelles V. Clin Res HIV AIDS.2022;8(1):1053. https://pubmed.ncbi.nlm.nih.gov/36589263/. PMID: 36589263.
PUBMEDEarly Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19
Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19. Rodríguez-Mora S, Corona M, Torres M, Casado-Fernández G, García-Pérez J, Ramos-Martín F, Vigón L, Manzanares M, Mateos E, Martín-Moro F, Zurdo-Castronuño A, Murciano-Antón MA, Alcamí J, Pérez-Olmeda M, López-Jiménez J, García-Gutiérrez V, Coiras M (AC). J Clin Med. 2022 May 16;11(10):2803. doi: 10.3390/jcm11102803. PMID: 35628927.
PUBMED DOIChanges in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D
Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D. Torres M, Casado G, Vigón L, Rodríguez-Mora S, Mateos E, Ramos-Martín F, López-Wolf D, Sanz-Moreno J, Ryan-Murua P, Taboada-Martínez ML, López-Huertas MR, Cervero M, Coiras M (AC). Biomed Pharmacother. 2022 Apr 14;150:112965. doi: 10.1016/j.biopha.2022.112965. PMID: 35468580.
PUBMED DOIStrong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection.
Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection. Vigón L, Sánchez-Tornero A, Rodríguez-Mora S, García-Pérez J, Corona de Lapuerta M, Pérez-Lamas L, Casado-Fernández G, Moreno G, Torres M, Mateos E, Murciano-Antón MA, Alcamí J, Pérez-Olmeda M, López-Jiménez J, García-Gutiérrez V, Coiras M (AC). J Clin Med. 2022 Apr 11;11(8):2137. doi: 10.3390/jcm11082137. PMID: 35456230.
PUBMED DOIPersistent overactive cytotoxic immune response in a Spanish cohort of individuals with Long-COVID: Identification of diagnostic biomarkers
Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with Long-COVID: Identification of diagnostic biomarkers. Galán M, Vigón L, Fuertes D, Murciano-Antón MA, Casado-Fernández G, Domínguez-Mateos S, Mateos E, Ramos-Martín F, Planelles V, Torres M, Rodríguez-Mora S, López-Huertas MR, Coiras M (CA). Front Immunol. 2022 Mar 25;13:848886. doi: 10.3389/fimmu.2022.848886. PMID: 35401523
PUBMED DOIPharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence
Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence. Innis EA, Levinger C, Szaniawski MA, Williams ESCP, Alcamí J, Bosque A, Schiffer JT, Coiras M, Spivak AM, Planelles V. Biochem Pharmacol. 2021 Oct 26:114816. doi: 10.1016/j.bcp.2021.114816. PMID: 34715067.
PUBMED DOIImpaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU.
Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. Vigón L, García-Pérez J, Rodríguez-Mora S, Torres M, Mateos E, Castillo de la Osa M, Cervero M, Malo De Molina R, Navarro C, Murciano-Antón MA, García-Gutiérrez V, Planelles V, Alcamí J, Pérez-Olmeda M, López-Huertas MR, Coiras M (AC). Front Immunol. 2021 Sep 20;12:742631. doi: 10.3389/fimmu.2021.742631. eCollection 2021. PMID: 34616404.
PUBMED DOIProvirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Vigón L, Martínez-Román P, Rodríguez-Mora S, Torres M, Puertas MC, Mateos E, Salgado M, Navarro A, Sánchez-Conde M, Ambrosioni J, Cervero M, Wyen C, Hoffmann C, Miró JM, Alcamí J, Podzamczer D, García-Gutiérrez V, Martínez-Picado J, Briz V, Rosa López-Huertas M, Planelles V, Coiras M (AC). Biochem Pharmacol. 2021 Oct;192:114666. doi: 10.1016/j.bcp.2021.114666. PMID: 34186065.
PUBMED DOIImpaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity.
Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Vigón L, Fuertes D, García-Pérez J, Torres M, Rodríguez-Mora S, Mateos E, Corona M, Saez-Marín AJ, Malo R, Navarro C, Murciano-Antón MA, Cervero M, Alcamí J, García-Gutiérrez V, Planelles V, López-Huertas MR, Coiras M (AC). Front Immunol. 2021 May 26;12:665329. doi: 10.3389/fimmu.2021.665329. eCollection 2021. PMID: 34122423.
PUBMED DOIIdentification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Vigón L, Luna A, Galán M, Rodríguez-Mora S, Fuertes D, Mateos E, Piris-Villaespesa M, Bautista G, San José E, Rivera-Torres J, Steegmann JL, de Ory F, Pérez-Olmeda M, Alcamí J, Planelles V, López-Huertas MR, García-Gutiérrez V, Coiras M (AC). J Clin Med. 2020 Dec 25;10(1):42. doi: 10.3390/jcm10010042. PMID: 33375572.
PUBMED DOICytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Vigón L, Rodríguez-Mora S, Luna A, Sandonís V, Mateos E, Bautista G, Steegmann JL, Climent N, Plana M, Pérez-Romero P, de Ory F, Alcamí J, García-Gutierrez V, Planelles V, López-Huertas MR, Coiras M (AC). Biochem Pharmacol. 2020 Dec;182:114203. doi: 10.1016/j.bcp.2020.114203. PMID: 32828803.
PUBMED DOITyrosine Kinase Inhibition: a New Perspective in the Fight against HIV
Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Rodríguez-Mora S, Spivak AM, Szaniawski MA, López-Huertas MR, Alcamí J, Planelles V, Coiras M (AC). Curr HIV/AIDS Rep. 2019 Oct;16(5):414-422. doi: 10.1007/s11904-019-00462-5. PMID: 31506864. Review.
PUBMED DOIDasatinib protects humanized mice from acute HIV-1 infection
Dasatinib protects humanized mice from acute HIV-1 infection. Salgado M, Martinez-Picado J, Gálvez C, Rodríguez-Mora S, Rivaya B, Urrea V, Mateos E, Alcamí J, Coiras M (AC). Biochem Pharmacol. 2020 Apr;174:113625. doi: 10.1016/j.bcp.2019.113625. PMID: 31476293.
PUBMED DOIEvaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M (AC). Biochem Pharmacol. 2018 Oct;156:248-264. doi: 10.1016/j.bcp.2018.08.031. PMID: 30142322.
PUBMED DOIStaphylococcus aureus Nasal Colonization in Spanish Children. The COSACO Nationwide Surveillance Study.
Staphylococcus aureus Nasal Colonization in Spanish Children. The COSACO Nationwide Surveillance Study. Del Rosal T, Méndez-Echevarría A, Garcia-Vera C, Escosa-Garcia L, Agud M, Chaves F, Román F, Gutierrez-Fernandez J, Ruiz de Gopegui E, Ruiz-Carrascoso G, Ruiz-Gallego MDC, Bernet A, Quevedo SM, Fernández-Verdugo AM, Díez-Sebastian J, Calvo C; COSACO Study Group.
PUBMEDAntimicrobial Resistance and Distribution of Staphylococcus spp. Pulsotypes Isolated from Goat and Sheep Bulk Tank Milk in Southern Spain
Antimicrobial Resistance and Distribution of Staphylococcus spp. Pulsotypes Isolated from Goat and Sheep Bulk Tank Milk in Southern Spain. Barrero-Domínguez B, Luque I, Galán-Relaño Á, Vega-Pla JL, Huerta B, Román F, Astorga RJ. Foodborne Pathog Dis. 2019 Oct;16(10):723-730. doi: 10.1089/fpd.2018.2593. Epub 2019 Jun 3.Foodborne Pathog Dis. 2019. PMID: 31157980
PUBMEDPrevalence of pSCFS7-like vectors among cfr-positive staphylococcal population in Spain
Prevalence of pSCFS7-like vectors among cfr-positive staphylococcal population in Spain. Nguyen LTT*, Román F*, Morikawa K, Trincado P, Marcos C, Rojo-Martín MD, Cafini F. Int J Antimicrob Agents. 2018 Aug;52(2):305-306.
PUBMEDMethodology for the Study of Horizontal Gene Transfer in Staphylococcus aureus.
Methodology for the Study of Horizontal Gene Transfer in Staphylococcus aureus. Cafini F, Thi Le Thuy N, Román F, Prieto J, Dubrac S, Msadek T, Morikawa K. J Vis Exp. 2017 Mar 10;(121).
PUBMEDEmergence of cfr-Mediated Linezolid Resistance in a Methicillin-Resistant Staphylococcus aureus Epidemic Clone Isolated from Patients with Cystic Fibrosis.
Emergence of cfr-Mediated Linezolid Resistance in a Methicillin-Resistant Staphylococcus aureus Epidemic Clone Isolated from Patients with Cystic Fibrosis. de Dios Caballero J, Pastor MD, Vindel A, Máiz L, Yagüe G, Salvador C, Cobo M, Morosini MI, del Campo R, Cantón R; GEIFQ Study Group. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1878-82.
PUBMEDMolecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Spain: 2004-12.
Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Spain: 2004-12. Vindel A, Trincado P, Cuevas O, Ballesteros C, Bouza E, Cercenado E. J Antimicrob Chemother. 2014 Nov;69(11):2913-9.
PUBMEDDraft Genome Sequence of Strain SA_ST125_MupR of Methicillin-Resistant Staphylococcus aureus ST125, a Major Clone in Spain.
Draft Genome Sequence of Strain SA_ST125_MupR of Methicillin-Resistant Staphylococcus aureus ST125, a Major Clone in Spain. Barrado L, Viedma E, Vindel A, Otero JR, Chaves F. Genome Announc. 2013 Aug 8;1(4).
PUBMEDDetection of linezolid-resistant Staphylococcus aureus with 23S rRNA and novel L4 riboprotein mutations in a cystic fibrosis patient in Spain.
Detection of linezolid-resistant Staphylococcus aureus with 23S rRNA and novel L4 riboprotein mutations in a cystic fibrosis patient in Spain. Román F, Roldán C, Trincado P, Ballesteros C, Carazo C, Vindel A. Antimicrob Agents Chemother. 2013 May;57(5):2428-9.
PUBMED9: Harvala H, Broberg E, Benschop K, Berginc N, Ladhani S, Susi P, Christiansen C, McKenna J, Allen D, Makiello P, McAllister G, Ca
9: Harvala H, Broberg E, Benschop K, Berginc N, Ladhani S, Susi P, Christiansen C, McKenna J, Allen D, Makiello P, McAllister G, Carmen M, Zakikhany K, Dyrdak R, Nielsen X, Madsen T, Paul J, Moore C, von Eije K, Piralla A, Carlier M, Vanoverschelde L, Poelman R, Anton A, López-Labrador FX, Pellegrinelli L, Keeren K, Maier M, Cassidy H, Derdas S, Savolainen-Kopra C, Diedrich S, Nordbø S, Buesa J, Bailly JL, Baldanti F, MacAdam A, Mirand A, Dudman S, Schuffenecker I, Kadambari S, Neyts J, Griffiths MJ, Richter J, Margaretto C, Govind S, Morley U, Adams O, Krokstad S, Dean J, Pons-Salort M, Prochazka B, Cabrerizo M, Majumdar M, Nebbia G, Wiewel M, Cottrell S, Coyle P, Martin J, Moore C, Midgley S, Horby P, Wolthers K, Simmonds P, Niesters H, Fischer TK. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. J Clin Virol. 2018 Apr; 101:11-17. doi: 10.1016/j.jcv.2018.01.008. Epub 2018 Feb 6. PMID: 29414181.
Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19. García-Ríos, E.; Leivas, A.; Mancebo, F.J.; Sánchez-Vega, L.; Lanzarot, D.; Aguado, J.M.; Martínez-López, J.; Paciello, M.L.; Pérez-Romero, P. Biomedicines 2022, 10, 630. doi: 10.3390/biomedicines10030630.
Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19. García-Ríos, E.; Leivas, A.; Mancebo, F.J.; Sánchez-Vega, L.; Lanzarot, D.; Aguado, J.M.; Martínez-López, J.; Paciello, M.L.; Pérez-Romero, P. Biomedicines 2022, 10, 630. doi: 10.3390/biomedicines10030630.
Deciphering the Potential Coding of Human Cytomegalovirus: New Predicted Transmembrane Proteome. Mancebo, F.J., Parras-Moltó, M., García-Ríos, E., Pérez-Romero, P. International Journal of Molecular Sciences, 2022, 23(5), 2768. doi: 10.3390/ijms23052768.
Deciphering the Potential Coding of Human Cytomegalovirus: New Predicted Transmembrane Proteome. Mancebo, F.J., Parras-Moltó, M., García-Ríos, E., Pérez-Romero, P. International Journal of Molecular Sciences, 2022, 23(5), 2768. doi: 10.3390/ijms23052768.
Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance
Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. Tajuelo, A.; López-Siles, M.; Más, V.; Pérez-Romero, P.; Aguado, J.M.; Briz, V.; McConnell, M.J.; Martín-Galiano, A.J.; López, D. Int. J. Mol. Sci. 2022, 23, 2977. doi: 10.3390/ijms23062977.
PUBMEDDetection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency. Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vázquez P, Carretero O, Gil-Etayo FJ, Suàrez-Fernández P, Pérez-Romero, P, Rodríguez de Frías E, Serrano A, Allende LM, Pleguezuelo D, Paz-Artal E. J Clin Immunol. 2022 Feb;42(2):240-252. doi: 10.1007/s10875-021-01174-5. PMID: 34787773.
PUBMEDOptimization of a Lambda-RED Recombination Method for Rapid Gene Deletion in Human Cytomegalovirus
Optimization of a Lambda-RED Recombination Method for Rapid Gene Deletion in Human Cytomegalovirus. García-Ríos E, Gata-de-Benito J, López-Siles M, McConnell MJ, Pérez-Romero, P. Int J Mol Sci. 2021 Sep 29;22(19):10558. doi: 10.3390/ijms221910558. PMID: 34638896.
PUBMEDCirculatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients
Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients. Suàrez-Fernández P, Utrero-Rico A, Sandonis V, García-Ríos E, Arroyo-Sánchez D, Fernández-Ruiz M, Andrés A, Polanco N, González-Cuadrado C, Almendro-Vázquez P, Pérez-Romero P, Aguado JM, Paz-Artal E, Laguna-Goya R. Am J Transplant. 2021 Dec;21(12):3946-3957. doi: 10.1111/ajt.16725. PMID: 34153157.
PUBMEDIs It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?
Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients? García-Ríos E, Nuévalos M, Mancebo FJ, Pérez-Romero P. Front Immunol. 2021 Apr 23;12:657144. doi: 10.3389/fimmu.2021.657144. PMID: 33968058.
PUBMEDCytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Vigón L, Rodríguez-Mora S, Luna A, Sandonís V, Mateos E, Bautista G, Steegmann JL, Climent N, Plana M, Pérez-Romero P, de Ory F, Alcamí J, García-Gutierrez V, Planelles V, López-Huertas MR, Coiras M. Biochem Pharmacol. 2020 Aug 20;182:114203. doi: 10.1016/j.bcp.2020.114203. PMID: 32828803
PUBMEDRole of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches
Role of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches. Sandonís V, García-Ríos E, McConnell MJ, Pérez-Romero P.Sandonís V, et al. Trends Microbiol. 2020 Nov;28(11):900-912. doi: 10.1016/j.tim.2020.04.003. PMID: 32448762 Review.
PUBMEDPre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients
Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients. Aydillo T, Escalera A, Strohmeier S, Aslam S, Sanchez-Cespedes J, Ayllon J, Roca-Oporto C, Pérez-Romero P, Montejo M, Gavalda J, Munoz P, Lopez-Medrano F, Carratala J, Krammer F, García-Sastre A, Cordero E. Cell Rep Med. 2020 Nov 3;1(8):100130. doi: 10.1016/j.xcrm.2020.100130. PMID: 33294855
PUBMEDEffect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients. Cordero E, Bulnes-Ramos A, Aguilar-Guisado M, González Escribano F, Olivas I, Torre-Cisneros J, Gavaldá J, Aydillo T, Moreno A, Montejo M, Fariñas MC, Carratalá J, Muñoz P, Blanes M, Fortún J, Suárez-Benjumea A, López-Medrano F, Roca C, Lara R, Pérez-Romero P. Front Immunol. 2020 Oct 6;11:1917. doi: 10.3389/fimmu.2020.01917. PMID: 33123119
Effect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients. Cordero E, Bulnes-Ramos A, Aguilar-Guisado M, González Escribano F, Olivas I, Torre-Cisneros J, Gavaldá J, Aydillo T, Moreno A, Montejo M, Fariñas MC, Carratalá J, Muñoz P, Blanes M, Fortún J, Suárez-Benjumea A, López-Medrano F, Roca C, Lara R, Pérez-Romero P. Front Immunol. 2020 Oct 6;11:1917. doi: 10.3389/fimmu.2020.01917. PMID: 33123119
Humoral response to natural influenza infection in solid organ transplant recipients
Humoral response to natural influenza infection in solid organ transplant recipients. Hirzel C, Ferreira VH, L'Huillier AG, Hoschler K, Cordero E, Limaye AP, Englund JA, Reid G, Humar A, Kumar D; Influenza in Transplant Study Group.Hirzel C, et al. Am J Transplant. 2019 Aug;19(8):2318-2328. doi: 10.1111/ajt.15296. Epub 2019 Mar 18.Am J Transplant. 2019. PMID: 30748090 Clinical Trial.
PUBMEDA 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients
A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. Kumar D, Ferreira VH, Blumberg E, Silveira F, Cordero E, Perez-Romero P, Aydillo T, Danziger-Isakov L, Limaye AP, Carratala J, Munoz P, Montejo M, Lopez-Medrano F, Farinas MC, Gavalda J, Moreno A, Levi M, Fortun J, Torre-Cisneros J, Englund JA, Natori Y, Husain S, Reid G, Sharma TS, Humar A.Kumar D, et al. Clin Infect Dis. 2018 Oct 15;67(9):1322-1329. doi: 10.1093/cid/ciy294.Clin Infect Dis. 2018. PMID: 29635437 Clinical Trial.
PUBMEDImpact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study
Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Molina-Ortega A, Martín-Gandul C, Mena-Romo JD, Rodríguez-Hernández MJ, Suñer M, Bernal C, Sánchez M, Sánchez-Céspedes J, Pérez Romero P, Cordero E.Molina-Ortega A, et al. Clin Microbiol Infect. 2019 Jun;25(6):753-758. doi: 10.1016/j.cmi.2018.09.019. PMID: 30292792 Clinical Trial.
PUBMEDTwo Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial.
Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavaldà J, Moreno A, Torre-Cisneros J, Montejo JM, Fortun J, Muñoz P, Sabé N, Fariñas MC, Blanes-Julia M, López-Medrano F, Suárez-Benjumea A, Martinez-Atienza J, Rosso-Fernández C, Pérez-Romero P. Clin Infect Dis. 2017 Apr 1;64(7):829-838. doi: 10.1093/cid/ciw855.Clin Infect Dis. 2017. PMID: 28362949 Clinical Trial.
PUBMEDUse of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation
Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation. Blanco-Lobo P, Cordero E, Martín-Gandul C, Gentil MA, Suárez-Artacho G, Sobrino M, Aznar J, Pérez-Romero P.Blanco-Lobo P, et al. J Infect. 2016 May;72(5):597-607. doi: 10.1016/j.jinf.2016.02.008. Epub 2016 Feb 24.J Infect. 2016. PMID: 26920791 Clinical Trial.
PUBMEDIdentification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development
Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development. Corral-Lugo A, López-Siles M, López D, McConnell MJ, Martin-Galiano AJ. Vaccines. 2020 Jul 20;8(3):397. doi: 10.3390/vaccines8030397.
PUBMEDUsing Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria
Using Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria. Martín-Galiano AJ, McConnell MJ.Front Immunol. 2019 Dec 10;10:2841. doi: 10.3389/fimmu.2019.02841. eCollection 2019.
PUBMEDA lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection
A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection. Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ.Vaccine. 2020 Jan 22;38(4):719-724. doi: 10.1016/j.vaccine.2019.11.043.
PUBMEDA Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa.
A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa. Aguilera-Herce J, García-Quintanilla M, Romero-Flores R, McConnell MJ, Ramos-Morales F. mSphere. 2019 Apr 17;4(2):e00116-19. doi: 10.1128/mSphere.00116-19.
PUBMEDWhere are we with monoclonal antibodies for multidrug-resistant infections?
Where are we with monoclonal antibodies for multidrug-resistant infections? McConnell MJ. Drug Discov Today. 2019 May;24(5):1132-1138. doi: 10.1016/j.drudis.2019.03.002.
PUBMEDContent with Investigacion .
-
María Cabrerizo Sanz
Tenure Scientist and Group Leader
ORCID code: 0000-0001-7054-5696
Doctor in Chemistry, specializing in Biochemistry and Molecular Biology, Universidad Autónoma de Madrid (2000). Except for a postdoctoral period of 2 years at the Hospital de La Princesa, in which her research was related to onco-hematological diseases, the rest of her scientific career has focused on the study of infectious diseases caused by viruses and their surveillance. She joined the Instituto de Salud Carlos III in 2003, first in the Laboratory of Arbovirus and Imported Viral Diseases, then in the Laboratory of Viral Hepatitis and finally, in the Laboratory of Enterovirus (which is accredited as a National Polio Laboratory -LNP- for the WHO since 1998). She obtained the position of Tenure Scientist in 2016, at the same time she assumed the responsibility of the laboratory, currently of Enteric Viruses: Poliovirus/Enterovirus, Parechovirus and Gastroenteritis-producing Viruses, of the CNM. She has 4 scientific sexennials and 4 quinquennials recognized.
She has been and is PI of 4 consecutive research projects and 3 service contracts, from 2012 to the present, participating, in addition, in other 20 projects. As head of the LNP, she is part of the Working Group of the National Plan for the Eradication of Poliomyelitis and of the WHO European Polio Laboratory Network. She is also a member of the European Non-Polio Enterovirus Network (ENPEN), and of the national cooperation networks CIBERESP and RITIP (IdiPAZ). Since 2023 she is a Council Member from Spain of the European Society.
In total she has published 98 articles in WoS indexed journals (23 Q1 and 22 D1), being first author, senior author or correspondence author in 43 of them (H=27). She has supervised 1 PhD Thesis (2017) and 12 TFM. She is currently supervising another doctoral thesis (IMIENS-UNED). She participates as a teacher in three university masters (UCM, UAH and UV), being coordinator of the subject H2 of the Master of Virology at UCM.
-
Mª Dolores Fernández García
Tenure Scientist
ORCID code: 0000-0003-0336-6596
Degree in Pharmacy (2005) and PhD from the University VII Paris Diderot in Microbiology (2010). She completed her doctoral thesis at the Pasteur Institute in Paris characterizing the molecular and cellular basis of flavivirus entry into cells. Specialist in Public Health Microbiology (European Program EUPHEM coordinated by ECDC). She has worked 3 years for the French Ministry of Foreign Affairs as a researcher at the Pasteur Institute in Dakar (Senegal) carrying out microbiological surveillance activities and research on polioviruses and non-polio enteroviruses in West Africa. She has obtained two Miguel Servet contracts: one to work at IMIBIC in Cordoba (2019) and an intramural one to work at CNM (2020). Both were awarded for the study of neurotropic viruses applying massive sequencing for their diagnosis. In 2021 he joined the CNM-ISCIII as a Tenure Research Scientist at the Enterovirus and Viral Gastroenteritis Unit of the CNM-ISCIII. Since then, she combines her scientific activity with the assistance to the National Health System in the microbiological research of outbreaks and in the Genomic Surveillance of Enteroviruses and Gastroenteritis-producing Viruses.
She is a researcher in the Epidemiology and Public Health Area of the Centro de Investigación Biomédica en Red (CIBERESP-ISCIII). In addition, she is an evaluator and panelist for the HORIZON health program projects of the European Commission, the French National Agency ANRS-Emerging Infectious Diseases, R&D&I in HEALTH of the Strategic Action in Health (ISCIII) and the Andalusian Public Foundation Progreso y Salud. She has worked as scientific advisor to the Spanish Ministry of Health on Rotavirus and Polio. Since 2020 she has been teaching virology in different Spanish universities.
She has worked for WHO in the investigation of numerous outbreaks caused by viruses (Ebola, Zika, Yellow Fever, Dengue, etc.) in African and Asian countries strengthening laboratory capacities through technology transfer of diagnostic methods, training of laboratory personnel in these countries and scientific advisory tasks to the Ministries of Health. She has been the Health Coordinator of the START Project (Spanish Technical Aid Response Team) of the AECID, framed in the “Emergency Medical Teams” initiative of the WHO, participating in the establishment for Spain of a field hospital classified by the WHO as EMT Level 2 for interventions in humanitarian emergencies.
-
Carmen Serrano Risquez
Investigador predoctoral (CAM)
-
Juan Camacho Padilla
Investigador predoctoral (PFIS)
-
Yasmin Biya Assiry
Técnico de laboratorio en formación (PEJ-CAM)
-
Estrella Ruiz de Pedro
Técnico de laboratorio (PTA para Infraestructuras de I+D+I)
-
Rubén González Sanz
Técnico Superior Especializado OPI
-
Clara Martín Martín
Investigador predoctoral (PFIS)
-
Nazaret Díaz Sánchez
Técnico Superior Especializado OPI (apoyo)
-
Nerea García Ibáñez
Ayudante de Investigación de OPI. Técnico de laboratorio
-
Vanesa Recio Huertas
Ayudante de Investigación de OPI. Técnico de laboratorio (apoyo)
-
Ana Donoso Almenara
Contratada predoctoral pFIS
List of staff
Información adicional
This group constitutes the National Poliovirus Laboratory (Polio Eradication Plan), integrated into the European network WHO/EURO Polio Laboratory Network and coordinating, in turn, the National Network of Laboratories for the study of paralysis cases in Research on enterovirus and parechovirus infections in the pediatric population has been funded since 2013 through research projects (PI PI12/00904; PI15CIII/00020; PI18CIII/00017), of which María Cabrerizo is PI and in which epidemiologists (CNE) and pediatricians and microbiologists from more than 20 SNS hospitals participate.
The PI belongs to the consolidated research group RITIP-IdiPaz and CIBERESP. Since 1999, the group has been carrying out the virological study of environmental samples (wastewater and treated water) from the CAM, through a contract with the CYII. Finally, the group is responsible for the diagnosis and characterization of gastrointestinal infections caused by viruses (norovirus, rotavirus and others) and for the investigation of outbreaks (CS of the CNM).
This group constitutes the National Poliovirus Laboratory (Polio Eradication Plan), integrated into the European network WHO/EURO Polio Laboratory Network and coordinating, in turn, the National Network of Laboratories for the study of paralysis cases in Research on enterovirus and parechovirus infections in the pediatric population has been funded since 2013 through research projects (PI PI12/00904; PI15CIII/00020; PI18CIII/00017), of which María Cabrerizo is PI and in which epidemiologists (CNE) and pediatricians and microbiologists from more than 20 SNS hospitals participate.
The PI belongs to the consolidated research group RITIP-IdiPaz and CIBERESP. Since 1999, the group has been carrying out the virological study of environmental samples (wastewater and treated water) from the CAM, through a contract with the CYII. Finally, the group is responsible for the diagnosis and characterization of gastrointestinal infections caused by viruses (norovirus, rotavirus and others) and for the investigation of outbreaks (CS of the CNM).